Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial

Introduction: Anlotinib has brought about marked progression-free survival and overall survival benefit compared with placebos as third-line or further treatment in advanced NSCLC. Nevertheless, the safety and efficacy of concurrent anlotinib and chemoradiotherapy are still unclear. Methods: Patient...

Full description

Bibliographic Details
Main Authors: Hui Zhu, MD, Wenxiao Jia, PhD, Xuquan Jing, MD, Wei Huang, MD, Linlin Wang, MD, Jinming Yu, MD
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
Anlotinib
Thoracic radiotherapy
Pulmonary toxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000637

Similar Items

Similar Items